Drug Reference

Wegovy

semaglutide · Updated 2026-05-01 · Sources cited to FDA labeling

Wegovy (semaglutide) is a once-weekly injectable GLP-1 receptor agonist approved by the FDA for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition

Sources
  • FDA label: Wegovy (semaglutide) injection, NDA 215256, current labeling accessed January 2026
  • SELECT cardiovascular outcomes trial: Lincoff AM et al., NEJM 2023;389:2221-2232
  • STEP 1 trial: Wilding JPH et al., NEJM 2021;384:989-1002
  • STEP 2 trial: Davies M et al., Lancet 2021;397:971-984
  • STEP 4 trial: Rubino DM et al., JAMA 2021;325:1414-1425
  • FDA Drug Safety Communication: GLP-1 receptor agonists and ileus risk, 2024
  • FDA label supplement: cardiovascular risk reduction indication, NDA 215256/S-011, March 2024

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.